[go: up one dir, main page]

CN113508109A - 取代的杂环酰胺类化合物，其制法与医药上的用途 - Google Patents

取代的杂环酰胺类化合物，其制法与医药上的用途 Download PDF

Info

Publication number
CN113508109A
CN113508109A CN202080018174.4A CN202080018174A CN113508109A CN 113508109 A CN113508109 A CN 113508109A CN 202080018174 A CN202080018174 A CN 202080018174A CN 113508109 A CN113508109 A CN 113508109A
Authority
CN
China
Prior art keywords
added
substituted
ethyl acetate
thiazol
api
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080018174.4A
Other languages
English (en)
Other versions
CN113508109B (zh
Inventor
周福生
徐晓明
张磊涛
刘柱博
胡刚
丁茜
谢付波
郑彪
吕强
兰炯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinfang Pharmaceutical Technology (Shanghai) Co.,Ltd.
Zhejiang Genfleet Therapeutics Co Ltd
Original Assignee
Genfleet Therapeutics Shanghai Inc
Zhejiang Genfleet Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfleet Therapeutics Shanghai Inc, Zhejiang Genfleet Therapeutics Co Ltd filed Critical Genfleet Therapeutics Shanghai Inc
Publication of CN113508109A publication Critical patent/CN113508109A/zh
Application granted granted Critical
Publication of CN113508109B publication Critical patent/CN113508109B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一种对RIPK1具有选择抑制作用的取代的杂环酰胺类化合物及其药学上可接受的盐、立体异构体、溶剂化合物或前药，包含该化合物的药物组合物，及其在制备治疗RIPK1相关疾病或病症药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN202080018174.4A 2019-03-22 2020-03-20 取代的杂环酰胺类化合物，其制法与医药上的用途 Active CN113508109B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910221799 2019-03-22
CN201910221799X 2019-03-22
PCT/CN2020/080306 WO2020192562A1 (zh) 2019-03-22 2020-03-20 取代的杂环酰胺类化合物，其制法与医药上的用途

Publications (2)

Publication Number Publication Date
CN113508109A true CN113508109A (zh) 2021-10-15
CN113508109B CN113508109B (zh) 2023-02-10

Family

ID=72611351

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080018174.4A Active CN113508109B (zh) 2019-03-22 2020-03-20 取代的杂环酰胺类化合物，其制法与医药上的用途

Country Status (8)

Country Link
US (1) US20220177462A1 (zh)
EP (1) EP3943488A4 (zh)
JP (1) JP7323637B2 (zh)
KR (1) KR20210141665A (zh)
CN (1) CN113508109B (zh)
AU (1) AU2020246313B2 (zh)
CA (1) CA3131337C (zh)
WO (1) WO2020192562A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116234550A (zh) * 2020-09-23 2023-06-06 劲方医药科技(上海)有限公司 芳甲酰取代的三环化合物及其制法和用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220141321A (ko) * 2020-02-13 2022-10-19 젠플리트 테라퓨틱스 (상하이) 아이엔씨. 다이하이드로나프티리딘온 화합물, 이의 제조 방법 및 이의 의학적 용도
CN114262322A (zh) 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
WO2023174374A1 (zh) 2022-03-16 2023-09-21 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用
WO2024140970A1 (zh) * 2022-12-30 2024-07-04 广州市联瑞制药有限公司 双环类化合物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038116A2 (en) * 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
WO2009017822A2 (en) * 2007-08-02 2009-02-05 Amgen Inc. Pi3 kinase modulators and methods of use
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
CN106715422A (zh) * 2014-07-28 2017-05-24 忠南大学校产学协力团 新型茚衍生物、其制备方法以及包含其作为活性成分的用于预防或治疗视网膜疾病的药物组合物
WO2018148626A1 (en) * 2017-02-13 2018-08-16 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
CN109053630A (zh) * 2018-08-22 2018-12-21 中国人民解放军第二军医大学 一种苯并噻唑类衍生物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071523A1 (es) * 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038116A2 (en) * 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
WO2009017822A2 (en) * 2007-08-02 2009-02-05 Amgen Inc. Pi3 kinase modulators and methods of use
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
CN106715422A (zh) * 2014-07-28 2017-05-24 忠南大学校产学协力团 新型茚衍生物、其制备方法以及包含其作为活性成分的用于预防或治疗视网膜疾病的药物组合物
WO2018148626A1 (en) * 2017-02-13 2018-08-16 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
CN109053630A (zh) * 2018-08-22 2018-12-21 中国人民解放军第二军医大学 一种苯并噻唑类衍生物及其用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116234550A (zh) * 2020-09-23 2023-06-06 劲方医药科技(上海)有限公司 芳甲酰取代的三环化合物及其制法和用途
CN116234550B (zh) * 2020-09-23 2024-12-27 劲方医药科技(上海)股份有限公司 芳甲酰取代的三环化合物及其制法和用途

Also Published As

Publication number Publication date
AU2020246313A1 (en) 2021-10-21
AU2020246313B2 (en) 2022-08-04
KR20210141665A (ko) 2021-11-23
EP3943488A1 (en) 2022-01-26
CA3131337C (en) 2023-10-17
CN113508109B (zh) 2023-02-10
JP7323637B2 (ja) 2023-08-08
EP3943488A4 (en) 2022-09-07
JP2022528251A (ja) 2022-06-09
WO2020192562A1 (zh) 2020-10-01
US20220177462A1 (en) 2022-06-09
CA3131337A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
CN113508109B (zh) 取代的杂环酰胺类化合物，其制法与医药上的用途
CN112390818B (zh) 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
CN112047937B (zh) 四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物，其制法与医药上的用途
JP7097373B2 (ja) キナーゼ阻害剤としてのアミノトリアゾロピリジン
WO2020177629A1 (zh) 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
CN113365995A (zh) 免疫调节剂，组合物及其方法
CN117222650A (zh) 吡啶或嘧啶并环类化合物，其制法与医药上的用途
EP3632903B1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
AU2017359023A1 (en) 3-substituted propionic acids as alpha v integrin inhibitors
JP6305510B2 (ja) ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾロピリドン
CN106852142A (zh) 作为醛固酮合酶抑制剂的螺二胺衍生物
WO2015110999A1 (en) Ezh2 inhibitors and uses thereof
JP2023520843A (ja) Ｂｃｌ－２阻害剤
CN113302183A (zh) 环脲
JP7451765B2 (ja) Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途
CN113767092A (zh) 双杂环羰基取代的二氢吡唑类化合物,其制法与医药上的用途
KR20200083529A (ko) 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물
JP2022500418A (ja) 受容体相互作用タンパク質キナーゼ１阻害剤（ｒｉｐｋ１）としての１ｈ−インダゾールカルボキサミド
CN113429410A (zh) 多杂环取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途
JP7441477B2 (ja) ジヒドロナフチリドン系化合物、その調製方法及び医薬への使用
JP7406008B2 (ja) Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途
WO2021092525A1 (en) Wdr5 inhibitors and modulators
WO2022258052A1 (zh) 杂环内酰胺类化合物，其制法与医药上的用途
KR102614279B1 (ko) 테트라히드로옥세피노피리딘 화합물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 201203 floors 2, 3, 4 and 5, building 8, No. 1206, Zhangjiang Road, Shanghai (Shanghai) pilot Free Trade Zone, Shanghai, China

Applicant after: GENFLEET THERAPEUTICS (SHANGHAI) Inc.

Applicant after: Zhejiang JinFang Pharmaceutical Co.,Ltd.

Address before: 201203 floors 2, 3, 4 and 5, building 8, No. 1206, Zhangjiang Road, pilot Free Trade Zone, Pudong New Area, Shanghai

Applicant before: GENFLEET THERAPEUTICS (SHANGHAI) Inc.

Applicant before: Zhejiang JinFang Pharmaceutical Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Floor 2, 3, 4 and 5, building 8, No. 1206, Zhangjiang Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Patentee after: Jinfang Pharmaceutical Technology (Shanghai) Co.,Ltd.

Country or region after: China

Patentee after: Zhejiang JinFang Pharmaceutical Co.,Ltd.

Address before: 2nd, 3rd, 4th, and 5th floors, Building 8, No. 1206 Zhangjiang Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee before: GENFLEET THERAPEUTICS (SHANGHAI) Inc.

Country or region before: China

Patentee before: Zhejiang JinFang Pharmaceutical Co.,Ltd.